TaiwanJ Pharmaceuticals Co., Ltd.

TaiwanJ Pharmaceuticals Co., Ltd. is a specialty biotechnology company focused on the research, development, and commercialization of small molecule drugs intended to address unmet medical needs, particularly in chronic organ inflammation of metabolic, autoimmune, and infectious origins. Founded in 2011 and headquartered in Hsinchu, Taiwan, the company’s core therapeutic areas include liver inflammation and fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases such as autoimmune hepatitis, asthma, atopic dermatitis, and allergy-related disorders. TaiwanJ’s approach emphasizes the re-profiling of approved compounds—for instance, its lead drug candidates JKB-122 and JKB-121 are advanced through expedited regulatory pathways—to reduce development risk and time-to-market. Beyond these candidates, the company is building a pipeline of novel chemical entities and aims to offer therapies that balance effectiveness, safety, and cost efficiency compared to traditional steroids or biologic drugs. TaiwanJ Pharmaceuticals plays an important role in Taiwan’s health technology sector and actively seeks collaborations and strategic partnerships to advance its pipeline and expand its market presence.